Palisade Bio Inc
NASDAQ:PALI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sun Art Retail Group Ltd
HKEX:6808
|
CN |
Palisade Bio Inc
Research & Development
Palisade Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Palisade Bio Inc
NASDAQ:PALI
|
Research & Development
-$6.8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
5%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Palisade Bio Inc
Glance View
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 13 full-time employees. The company went IPO on 2006-12-20. The firm is focused on discovering, developing, and commercializing oral therapies that target diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery. Its LB1148 has been advanced to Phase III clinical trials for the return of bowel function indication, which is a protease inhibitor that helps to restore bowel function and reduce abdominal adhesions following surgery.
See Also
What is Palisade Bio Inc's Research & Development?
Research & Development
-6.8m
USD
Based on the financial report for Jun 30, 2025, Palisade Bio Inc's Research & Development amounts to -6.8m USD.
What is Palisade Bio Inc's Research & Development growth rate?
Research & Development CAGR 10Y
5%
Over the last year, the Research & Development growth was 18%. The average annual Research & Development growth rates for Palisade Bio Inc have been -23% over the past three years , -20% over the past five years , and 5% over the past ten years .
